IndraLab

Statements

Momelotinib inhibits JAK1. 12 / 12
1 2 1 | 1 6 1
reach
"Momelotinib inhibited JAK1 and JAK2 at nanomolar concentrations in in vitro assays, and reduced ex vivo formation of erythroid colonies from JAK2 -positive PV patients [22]."
28622623
tas
No evidence text available
| DOI
dgi
No evidence text available
signor
No evidence text available
Other
sparser
"Notably, both ruxolitinib and momelotinib inhibit JAK1 as well as JAK2, while pacritinib and fedratinib are relatively more specific for JAK2."
34140953
eidos
"Momelotinib inhibited JAK1 and JAK2 at nanomolar concentrations in in vitro assays , and reduced ex vivo formation of erythroid colonies from JAK2V617F-positive PV patients [ 22 ] ."
28622623
reach
"Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis."
37042865
tas
No evidence text available
19762238
reach
"28 Finally, momelotinib (also known as CYT-387) inhibits both JAK1 (IC 50 11 nm) and JAK2 (IC 50 18 nm), rather than JAK3 (IC 50 0.16 muM), although off-target effects (serine/threonine kinase IKBKE) have been described."
32676568
reach
"Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis."
28622623
reach
"Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis."
28622623
reach
"Momelotinib is a potent inhibitor of JAK1 and JAK2."
32394008